Imagion Biosystems Limited advises that the 200,000 Performance Rights issued to Directors of the Company under the Company Long-term Incentive Plan on 14 June 2018, and approved by shareholders at the Company’s Annual General Meeting held on 31 May 2018, have passed the continuous employment vesting condition and have now vested. Accordingly, the Company has today issued 200,000 Fully Paid Ordinary Shares to the Directors as approved by shareholders at the Annual General Meeting held on 31 May 2018.
Imagion Biosystems’ IND Application for MagSense® Phase 2 Clinical Trial Clears FDA Review
June 3, 2026
Imagion Biosystems, Ltd. (ASX: IBX) has announced that the US Food and Drug Administration (FDA) completed its review of the company’s investigational new drug (IND)